Anthony Marciano of Seelos Therapeutics (NASDAQ: SEEL) gave an overview of how the FDA approval process works for prescription drugs. He discussed his company and their plans to develop treatments in indications such as Depression, Parkinson’s Disease and rare “Orphan Diseases.” We had an in-depth discussion of the Global Suicide Epidemic, Seelos’ program (SLS-002) using Intranasal Ketamine, and plans to run clinical trials to study its effect in “Suicidality” initially in Post-Traumatic Stress Disorder “PTSD.”
The Barn Blog 
Sorry can’t make it I will be visiting my New Grandson Miles Jacob Zingale in Illinois
My son’s name is Miles – good choice! Godspeed to him and your family.
Can I bring my own Ketamine?
Most definitely.
We wish the young Zingale well. “Miles Jacob”? Why not Guiseppe Garibaldi Zingale- now that has a ring to it.